Explore the latest in targeted and immune therapies, including recent advances in precision therapies and in use of tumor checkpoint inhibitors.
This Viewpoint discusses the cardiotoxicity of ibrutinib and the need for further research and postmarketing regulation.
This single-arm, phase 2 nonrandomized clinical trial assesses the efficacy and safety of combined pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide in women with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This economic evaluation assesses the budget impact associated with adding avapritinib for metastatic or unresectable GIST in patients with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 variant or after 3 or more previous treatments to a hypothetical US health plan formulary.
This randomized clinical trial assesses the efficacy of nivolumab plus ipilimumab in the treatment of patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.
This nonrandomized clinical trial evaluates molecular recurrence and patient-reported outcomes after tyrosine kinase inhibitor discontinuation in US patients with chronic myeloid leukemia.
This cohort study evaluates whether interstitial lung abnormalities are associated with immune checkpoint inhibitor–induced interstitial lung disease in patients with nonlung cancers.
This nonrandomized clinical trial evaluates the use of doxorubicin and pembrolizumab in patients with metastatic/unresectable anthracycline-naive sarcoma.
This randomized clinical trial evaluates the efficacy and safety of nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer.
This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.
This cost-utility analysis compares the cost-utility of these novel agents and their combinations with or without BRAF gene testing guidance for treating newly diagnosed advanced melanoma with unknown BRAF status.
This multicenter cohort study characterizes the spectrum of multisystem immune-related adverse events, their association with survival, and risk factors for development, in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
This cohort study examines tumor mutational burden in patients with uncommon cancers not receiving immunotherapy as a biomarker associated with overall survival.
This cross-sectional study calculates the fragility of survival data in randomized clinical trials evaluating immune checkpoint inhibitors.
This narrative review discusses developments in pharmacotherapy for patients with advanced hepatocellular carcinoma.
This systematic review with meta-analysis compares the effectiveness of different vascular endothelial growth factor inhibitors, checkpoint inhibitors, or their combinations in patients with advanced hepatocellular carcinoma in the first-line or refractory settings.
This systematic review and network meta-analysis clarifies which first-line treatment is associated with the best tumor response among patients with extensive-stage small cell lung cancer (SCLC).
This clinical trial assesses the clinical use of site-specific treatment, including molecularly targeted therapy based on next-generation sequencing results, for Japanese patients with cancer of unknown primary site.
This case report describes a woman in her 70s with type 2 diabetes, hypertension, idiopathic thrombocytopenia, and metastatic cholangiocarcinoma with an fibroblast growth factor receptor 2 translocation.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: